## Establishment Labs (ESTA) — deep-dive (filings-first) ### Executive takeaway Establishment Labs is a global breast aesthetics & reconstruction medtech company whose core revenue engine is **Motiva silicone gel-filled breast implants**, now **FDA-approved in the U.S. (Sep 2024)** and sold globally via distributors and direct sales. ["Motiva Implants… centerpiece"](0001688757-25-000065|0) ["received FDA approval… September 2024"](0001688757-25-000019|0) The near-term equity debate tends to center on whether **U.S. mix + pricing** can drive sustained gross-margin expansion fast enough to offset a structurally higher opex base (commercial ramp + public company costs), while the company also services a meaningful term-loan load. ["higher selling prices… United States… positive impact on our gross margins"](0001688757-25-000065|0) ["$246.4 million was outstanding under the Credit Agreement"](0001688757-25-000065|0) --- # 1) “What is ESTA?” — business model, products, and why it’s differentiated ### 1.1 Core platform: Motiva Implants (and adjacent products) The company positions **Motiva Implants** as the “centerpiece” of its platform and highlights safety/outcomes differentiation via proprietary technologies (surface, RFID/serial identification, barrier layer, gel-shell configuration). ["Motiva Implants… centerpiece"](0001688757-25-000065|0) ["incorporate… SmoothSilk… Qid RFID… BluSeal… TrueMonobloc"](0001688757-25-000019|0) From the FY2024 10‑K, the company says it sells **five product families**, including Round/Ergonomix variants and **Flora Tissue Expander** (tissue expander is a key bridge into reconstruction workflows). ["commercially sell five product families"](0001688757-25-000019|0) ### 1.2 Go-to-market: distributors + direct sales (and consignment mechanics) In the latest 10‑Q, the company describes revenue primarily driven by Motiva and sold to: 1) distributors, and 2) direct sales to physicians/hospitals/clinics. ["two types of customers: (1) medical distributors and (2) direct sales"](0001688757-25-000065|0) Revenue recognition is straightforward (ship-date), **except** for a portion of direct sales that are **consignment** (recognized when notified that implantation occurred). ["recognized… at the time of shipment… except… consigned inventory"](0001688757-25-000065|0) ["revenue is recognized… product has been implanted"](0001688757-25-000065|0) --- # 2) Footprint & commercialization momentum (the “where” and “why now”) ### 2.1 Global scale + U.S. inflection The company states Motiva is commercially available broadly internationally and that U.S. commercialization is recent and meaningful. ["commercially available in over 90 countries… most recently… United States"](0001688757-25-000065|0) In the Q3’25 10‑Q, management quantifies **U.S. sales of $28.3 million for the nine months ended Sep 30, 2025**. ["generated $28.3 million… United States… nine months ended September 30, 2025"](0001688757-25-000065|0) ### 2.2 FY2024 geographic revenue mix (how diversified is the P&L?) The FY2024 10‑K provides revenue by region (USD, in thousands), showing a broadly diversified base with EMEA + Asia-Pacific largest. ["EMEA… 78,209"](0001688757-25-000019|0) ["Asia-Pacific… 48,408"](0001688757-25-000019|0) **Revenue by geography (FY2024 vs FY2023 vs FY2022)** *(USD millions; converted from “in thousands”)* | Region | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | EMEA | 78.209 ["EMEA… 78,209"](0001688757-25-000019|0) | 80.150 ["EMEA… 80,150"](0001688757-25-000019|0) | 62.419 ["EMEA… 62,419"](0001688757-25-000019|0) | | Latin America | 34.998 ["Latin America… 34,998"](0001688757-25-000019|0) | 48.891 ["Latin America… 48,891"](0001688757-25-000019|0) | 52.442 ["Latin America… 52,442"](0001688757-25-000019|0) | | Asia-Pacific | 48.408 ["Asia-Pacific… 48,408"](0001688757-25-000019|0) | 33.953 ["Asia-Pacific… 33,953"](0001688757-25-000019|0) | 45.844 ["Asia-Pacific… 45,844"](0001688757-25-000019|0) | | North America | 4.410 ["North America… 4,410"](0001688757-25-000019|0) | 2.157 ["North America… 2,157"](0001688757-25-000019|0) | 0.995 ["North America… 995"](0001688757-25-000019|0) | | **Total** | **166.025** ["Total revenue… 166,025"](0001688757-25-000019|0) | **165.151** ["Total revenue… 165,151"](0001688757-25-000019|0) | **161.700** ["Total revenue… 161,700"](0001688757-25-000019|0) | **Interpretation:** U.S./North America is still a small share of FY2024, but the company describes a step-change after FDA approval (Sep 2024) and explicitly calls out higher U.S. pricing benefiting gross margin in 2025. ["higher selling prices… United States… positive impact"](0001688757-25-000065|0) --- # 3) Financial performance (GAAP) — what the filings show ## 3.1 FY2024 vs FY2023 (10‑K) **Income statement snapshot (FY)** *(USD millions; from 10‑K “in thousands”)* | Metric | FY2024 | FY2023 | YoY | |---|---:|---:|---:| | Revenue | 166.025 ["Revenue… 166,025"](0001688757-25-000019|0) | 165.151 ["Revenue… 165,151"](0001688757-25-000019|0) | +0.5% (computed) ["Revenue… 166,025"](0001688757-25-000019|0) ["Revenue… 165,151"](0001688757-25-000019|0) | | Gross profit | 109.525 ["Gross profit… 109,525"](0001688757-25-000019|0) | 106.977 ["Gross profit… 106,977"](0001688757-25-000019|0) | +2.4% (computed) ["Gross profit… 109,525"](0001688757-25-000019|0) ["Gross profit… 106,977"](0001688757-25-000019|0) | | Gross margin | 66.0% ["Gross margin… 66.0"](0001688757-25-000019|0) | 64.8% ["Gross margin… 64.8"](0001688757-25-000019|0) | +120 bps (computed) ["Gross margin… 66.0"](0001688757-25-000019|0) ["Gross margin… 64.8"](0001688757-25-000019|0) | | SG&A | 139.806 ["Sales, general and administrative… 139,806"](0001688757-25-000019|0) | 145.575 ["Sales, general and administrative… 145,575"](0001688757-25-000019|0) | -4.0% (computed) ["Sales, general and administrative… 139,806"](0001688757-25-000019|0) ["Sales, general and administrative… 145,575"](0001688757-25-000019|0) | | R&D | 19.706 ["Research and development… 19,706"](0001688757-25-000019|0) | 26.428 ["Research and development… 26,428"](0001688757-25-000019|0) | -25.4% (computed) ["Research and development… 19,706"](0001688757-25-000019|0) ["Research and development… 26,428"](0001688757-25-000019|0) | | Loss from operations | (49.987) ["Loss from operations… (49,987)"](0001688757-25-000019|0) | (65.026) ["Loss from operations… (65,026)"](0001688757-25-000019|0) | improvement (computed) ["Loss from operations… (49,987)"](0001688757-25-000019|0) ["Loss from operations… (65,026)"](0001688757-25-000019|0) | | Net loss | (84.596) ["Net loss… (84,596)"](0001688757-25-000019|0) | (78.502) ["Net loss… (78,502)"](0001688757-25-000019|0) | worse (computed) ["Net loss… (84,596)"](0001688757-25-000019|0) ["Net loss… (78,502)"](0001688757-25-000019|0) | ### 3.2 Q3’25 acceleration (10‑Q) — evidence of U.S.-driven mix shift The Q3’25 10‑Q shows significant revenue growth and gross margin expansion YoY. **Quarterly results (Q3’25 vs Q3’24)** *(USD millions; “in thousands”)* | Metric | Q3’25 (ended Sep 30, 2025) | Q3’24 (ended Sep 30, 2024) | YoY | |---|---:|---:|---:| | Revenue | 53.782 ["Revenue… 53,782"](0001688757-25-000065|0) | 40.227 ["Revenue… 40,227"](0001688757-25-000065|0) | +33.8% (computed) ["Revenue… 53,782"](0001688757-25-000065|0) ["Revenue… 40,227"](0001688757-25-000065|0) | | Gross profit | 37.696 ["Gross profit… 37,696"](0001688757-25-000065|0) | 25.717 ["Gross profit… 25,717"](0001688757-25-000065|0) | +46.6% (computed) ["Gross profit… 37,696"](0001688757-25-000065|0) ["Gross profit… 25,717"](0001688757-25-000065|0) | | Gross margin | 70.1% ["Gross margin… 70.1"](0001688757-25-000065|0) | 63.9% ["Gross margin… 63.9"](0001688757-25-000065|0) | +620 bps (computed) ["Gross margin… 70.1"](0001688757-25-000065|0) ["Gross margin… 63.9"](0001688757-25-000065|0) | | Loss from operations | (4.025) ["Loss from operations… (4,025)"](0001688757-25-000065|0) | (13.139) ["Loss from operations… (13,139)"](0001688757-25-000065|0) | improvement (computed) ["Loss from operations… (4,025)"](0001688757-25-000065|0) ["Loss from operations… (13,139)"](0001688757-25-000065|0) | | Net loss | (11.146) ["Net loss… (11,146)"](0001688757-25-000065|0) | (16.682) ["Net loss… (16,682)"](0001688757-25-000065|0) | improvement (computed) ["Net loss… (11,146)"](0001688757-25-000065|0) ["Net loss… (16,682)"](0001688757-25-000065|0) | **Management’s stated “why” (Q3’25):** gross margin improved primarily due to **higher selling prices in the U.S.** ["Gross margin increased… attributable… sales within the United States… higher selling prices"](0001688757-25-000065|0) --- # 4) Balance sheet & capital structure — what you’re underwriting ## 4.1 FY2024 year-end balance sheet (10‑K) Key balance-sheet items (USD, in thousands): | Line item | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Cash & cash equivalents | 90,347 ["Cash and cash equivalents… 90,347"](0001688757-25-000019|0) | 40,035 ["Cash and cash equivalents… 40,035"](0001688757-25-000019|0) | | Total assets | 346,831 ["Total assets… 346,831"](0001688757-25-000019|0) | 268,641 ["Total assets… 268,641"](0001688757-25-000019|0) | | Note payable (Oaktree), net | 219,577 ["Note payable, Oaktree… 219,577"](0001688757-25-000019|0) | 188,739 ["Note payable, Oaktree… 188,739"](0001688757-25-000019|0) | | Total liabilities | 293,736 ["Total liabilities… 293,736"](0001688757-25-000019|0) | 250,246 ["Total liabilities… 250,246"](0001688757-25-000019|0) | | Total shareholders’ equity | 53,095 ["Total shareholders’ equity… 53,095"](0001688757-25-000019|0) | 18,395 ["Total shareholders’ equity… 18,395"](0001688757-25-000019|0) | ## 4.2 Debt: term-loan structure & interest dynamics (10‑Q + 10‑K notes) As of **Sep 30, 2025**, the company discloses **$246.4 million outstanding under the Credit Agreement**, including capitalized accrued interest into principal. ["As of September 30, 2025… $246.4 million was outstanding"](0001688757-25-000065|0) At FY2024 year-end, the company discloses **$221.4 million outstanding** under the Credit Agreement. ["As of December 31, 2024, $221.4 million was outstanding"](0001688757-25-000019|0) **Why this matters:** the equity story is not just “revenue growth,” but also whether operating leverage can outpace interest expense (which is material in both FY and YTD disclosures). ["Interest expense… (20,829)"](0001688757-25-000019|0) ["Interest expense… (18,012)"](0001688757-25-000065|0) --- # 5) Cash flow & liquidity — how runway is managed ## 5.1 FY cash movement (10‑K) The FY2024 10‑K cash flow section shows year-end cash **$90.347 million**. ["Cash and cash equivalents at end of period… 90,347"](0001688757-25-000019|0) ## 5.2 9M’25 cash flow (10‑Q) For the **nine months ended Sep 30, 2025**, cash flow disclosure shows net cash used in operations and net decrease in cash. ["Operating activities… (50,728)"](0001688757-25-000065|0) ["Net increase/(decrease) in cash… (19,723)"](0001688757-25-000065|0) --- # 6) Near-term updates (2026 8‑Ks) — what changed *after* the last 10‑Q ## 6.1 Preliminary FY2025 results (Jan 12, 2026 press release furnished via 8‑K) The company disclosed **preliminary unaudited** ranges: - **Q4 2025 revenue:** $64.0–$65.0 million. ["Revenue… quarter ended December 31, 2025… between $64.0 million and $65.0 million"](0001688757-26-000004|1) - **FY2025 revenue:** $210.5–$211.5 million (≈27% growth vs 2024), including **U.S. Motiva sales $45.4–$45.9 million**. ["Revenue for fiscal year 2025… $210.5 million to $211.5 million"](0001688757-26-000004|1) ["including… $45.4 million and $45.9 million… United States"](0001688757-26-000004|1) - **Year-end 2025 cash:** ≈$75.5 million. ["year-end 2025 cash position… approximately $75.5 million"](0001688757-26-000004|1) ## 6.2 JPMorgan Healthcare Conference disclosure (Jan 14, 2026 8‑K) The company filed an 8‑K stating it **presented at the J.P. Morgan Healthcare Conference** and furnished materials as Exhibit 99.1. ["presented at the J.P. Morgan Healthcare Conference"](0001688757-26-000008|0) ["presentation materials… Exhibit 99.1"](0001688757-26-000008|0) --- # 7) Governance & incentives — what management is paid to do (Proxy: DEF 14A) ## 7.1 Board structure and declassification The 2025 proxy describes the board declassification process (phased in, concluding at the 2026 annual meeting). ["declassification… phased-in… concluding… 2026"](0001688757-25-000026|0) ## 7.2 Named executive officer (NEO) compensation (FY2024) — key table Below is the **Summary Compensation Table for FY2024** (USD): | Executive | Role | FY2024 Total comp | |---|---|---:| | Juan José Chacón Quirós | Former CEO | 2,601,271 ["Total… 2,601,271"](0001688757-25-000026|0) | | Filippo “Peter” Caldini | Interim CEO (joined Aug 2024) | 1,227,500 ["Total… 1,227,500"](0001688757-25-000026|0) | | Rajbir S. Denhoy | CFO | 1,120,391 ["Total… 1,120,391"](0001688757-25-000026|0) | | S. Ross Mansbach | General Counsel & CCO | 1,060,152 ["Total… 1,060,152"](0001688757-25-000026|0) | The same proxy breaks out **base salaries**, **target bonuses**, and **bonuses earned** for 2024. ["2024 Base Salary… 750,000"](0001688757-25-000026|0) ["2024 Target Bonus… 750,000"](0001688757-25-000026|0) ["2024 Bonus Earned… 487,500"](0001688757-25-000026|0) --- # 8) Risk map (from filings) — what can break the story ### 8.1 Regulatory & quality systems risk The company explicitly highlights reliance on maintaining (and obtaining) regulatory clearances/approvals and the potential for adverse impact if denied/delayed. ["Products… require clearance from the FDA… no assurance"](0001688757-25-000065|0) ### 8.2 Manufacturing concentration (Costa Rica) + capacity scaling Manufacturing is concentrated in Costa Rica and scaling requires time/certification; management notes the risk of being unable to fill orders if demand rises faster than capacity. ["manufactured… facilities in Costa Rica"](0001688757-25-000065|0) ["unable to fill all incoming orders"](0001688757-25-000019|0) ### 8.3 Supplier concentration The company describes reliance on a single-source supplier for medical-grade implantable silicone (Avantor). ["single-source… Avantor"](0001688757-25-000065|0) ### 8.4 Leverage + capital markets dependence Management states it may need to raise additional capital and warns about dilution / covenants, consistent with the debt burden disclosed. ["may seek to sell equity… or… debt financing"](0001688757-25-000065|0) ["$246.4 million was outstanding"](0001688757-25-000065|0) --- # 9) “Interactive” exploration paths (use this like a dashboard) Pick any path below as a lens; each is grounded in where the filings put the key facts. ### Path A — U.S. launch economics Focus on: U.S. sales growth, pricing/mix, gross margin expansion, and sales force productivity. ["Motiva… sales within the United States… higher selling prices"](0001688757-25-000065|0) ["generated $28.3 million… United States"](0001688757-25-000065|0) ### Path B — Operating leverage vs interest burden Focus on: SG&A trajectory vs gross profit growth, and interest expense / debt balance. ["SG&A… 121,041"](0001688757-25-000065|0) ["Interest expense… (18,012)"](0001688757-25-000065|0) ["$246.4 million… outstanding"](0001688757-25-000065|0) ### Path C — Geographic resilience Focus on: regional revenue shifts (EMEA/LatAm/APAC) and FX sensitivity. ["Revenue increased… Latin America… Asia-Pacific… EMEA"](0001688757-25-000065|0) ["fluctuations in currency exchange rates"](0001688757-25-000065|0) ### Path D — Governance & incentives Focus on: what the comp committee weights (revenue, opex, cash balance) and how equity awards vest. ["35%… revenue targets… 25%… OPEX… 25%… year-end cash balance"](0001688757-25-000026|0) ["vest over a four-year period"](0001688757-25-000026|0) --- If you want a “single-screen” underwriting view, the highest-signal filing anchors are: **FY2024 10‑K (filed Feb 28, 2025)**, **Q3’25 10‑Q (filed Nov 7, 2025)**, and the **Jan 2026 8‑Ks with preliminary FY2025 results**. ["filed… February 28, 2025"](0001688757-25-000065|0) ["filing_date… 20251107"](0001688757-25-000065|0) ["preliminary unaudited financial results… fiscal year ended December 31, 2025"](0001688757-26-000004|1)

## Establishment Labs (ESTA) — deep-dive (filings-first) ### Executive takeaway Establishment Labs is a global breast aesthetics & reconstruction medtech company whose core revenue engine is **Motiva silicone gel-filled breast implants**, now **FDA-approved in the U.S. (Sep 2024)** and sold globally via distributors and direct sales. ["Motiva Implants… centerpiece"](0001688757-25-000065|0) ["received FDA approval… September 2024"](0001688757-25-000019|0) The near-term equity debate tends to center on whether **U.S. mix + pricing** can drive sustained gross-margin expansion fast enough to offset a structurally higher opex base (commercial ramp + public company costs), while the company also services a meaningful term-loan load. ["higher selling prices… United States… positive impact on our gross margins"](0001688757-25-000065|0) ["$246.4 million was outstanding under the Credit Agreement"](0001688757-25-000065|0) --- # 1) “What is ESTA?” — business model, products, and why it’s differentiated ### 1.1 Core platform: Motiva Implants (and adjacent products) The company positions **Motiva Implants** as the “centerpiece” of its platform and highlights safety/outcomes differentiation via proprietary technologies (surface, RFID/serial identification, barrier layer, gel-shell configuration). ["Motiva Implants… centerpiece"](0001688757-25-000065|0) ["incorporate… SmoothSilk… Qid RFID… BluSeal… TrueMonobloc"](0001688757-25-000019|0) From the FY2024 10‑K, the company says it sells **five product families**, including Round/Ergonomix variants and **Flora Tissue Expander** (tissue expander is a key bridge into reconstruction workflows). ["commercially sell five product families"](0001688757-25-000019|0) ### 1.2 Go-to-market: distributors + direct sales (and consignment mechanics) In the latest 10‑Q, the company describes revenue primarily driven by Motiva and sold to: 1) distributors, and 2) direct sales to physicians/hospitals/clinics. ["two types of customers: (1) medical distributors and (2) direct sales"](0001688757-25-000065|0) Revenue recognition is straightforward (ship-date), **except** for a portion of direct sales that are **consignment** (recognized when notified that implantation occurred). ["recognized… at the time of shipment… except… consigned inventory"](0001688757-25-000065|0) ["revenue is recognized… product has been implanted"](0001688757-25-000065|0) --- # 2) Footprint & commercialization momentum (the “where” and “why now”) ### 2.1 Global scale + U.S. inflection The company states Motiva is commercially available broadly internationally and that U.S. commercialization is recent and meaningful. ["commercially available in over 90 countries… most recently… United States"](0001688757-25-000065|0) In the Q3’25 10‑Q, management quantifies **U.S. sales of $28.3 million for the nine months ended Sep 30, 2025**. ["generated $28.3 million… United States… nine months ended September 30, 2025"](0001688757-25-000065|0) ### 2.2 FY2024 geographic revenue mix (how diversified is the P&L?) The FY2024 10‑K provides revenue by region (USD, in thousands), showing a broadly diversified base with EMEA + Asia-Pacific largest. ["EMEA… 78,209"](0001688757-25-000019|0) ["Asia-Pacific… 48,408"](0001688757-25-000019|0) **Revenue by geography (FY2024 vs FY2023 vs FY2022)** *(USD millions; converted from “in thousands”)* | Region | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | EMEA | 78.209 ["EMEA… 78,209"](0001688757-25-000019|0) | 80.150 ["EMEA… 80,150"](0001688757-25-000019|0) | 62.419 ["EMEA… 62,419"](0001688757-25-000019|0) | | Latin America | 34.998 ["Latin America… 34,998"](0001688757-25-000019|0) | 48.891 ["Latin America… 48,891"](0001688757-25-000019|0) | 52.442 ["Latin America… 52,442"](0001688757-25-000019|0) | | Asia-Pacific | 48.408 ["Asia-Pacific… 48,408"](0001688757-25-000019|0) | 33.953 ["Asia-Pacific… 33,953"](0001688757-25-000019|0) | 45.844 ["Asia-Pacific… 45,844"](0001688757-25-000019|0) | | North America | 4.410 ["North America… 4,410"](0001688757-25-000019|0) | 2.157 ["North America… 2,157"](0001688757-25-000019|0) | 0.995 ["North America… 995"](0001688757-25-000019|0) | | **Total** | **166.025** ["Total revenue… 166,025"](0001688757-25-000019|0) | **165.151** ["Total revenue… 165,151"](0001688757-25-000019|0) | **161.700** ["Total revenue… 161,700"](0001688757-25-000019|0) | **Interpretation:** U.S./North America is still a small share of FY2024, but the company describes a step-change after FDA approval (Sep 2024) and explicitly calls out higher U.S. pricing benefiting gross margin in 2025. ["higher selling prices… United States… positive impact"](0001688757-25-000065|0) --- # 3) Financial performance (GAAP) — what the filings show ## 3.1 FY2024 vs FY2023 (10‑K) **Income statement snapshot (FY)** *(USD millions; from 10‑K “in thousands”)* | Metric | FY2024 | FY2023 | YoY | |---|---:|---:|---:| | Revenue | 166.025 ["Revenue… 166,025"](0001688757-25-000019|0) | 165.151 ["Revenue… 165,151"](0001688757-25-000019|0) | +0.5% (computed) ["Revenue… 166,025"](0001688757-25-000019|0) ["Revenue… 165,151"](0001688757-25-000019|0) | | Gross profit | 109.525 ["Gross profit… 109,525"](0001688757-25-000019|0) | 106.977 ["Gross profit… 106,977"](0001688757-25-000019|0) | +2.4% (computed) ["Gross profit… 109,525"](0001688757-25-000019|0) ["Gross profit… 106,977"](0001688757-25-000019|0) | | Gross margin | 66.0% ["Gross margin… 66.0"](0001688757-25-000019|0) | 64.8% ["Gross margin… 64.8"](0001688757-25-000019|0) | +120 bps (computed) ["Gross margin… 66.0"](0001688757-25-000019|0) ["Gross margin… 64.8"](0001688757-25-000019|0) | | SG&A | 139.806 ["Sales, general and administrative… 139,806"](0001688757-25-000019|0) | 145.575 ["Sales, general and administrative… 145,575"](0001688757-25-000019|0) | -4.0% (computed) ["Sales, general and administrative… 139,806"](0001688757-25-000019|0) ["Sales, general and administrative… 145,575"](0001688757-25-000019|0) | | R&D | 19.706 ["Research and development… 19,706"](0001688757-25-000019|0) | 26.428 ["Research and development… 26,428"](0001688757-25-000019|0) | -25.4% (computed) ["Research and development… 19,706"](0001688757-25-000019|0) ["Research and development… 26,428"](0001688757-25-000019|0) | | Loss from operations | (49.987) ["Loss from operations… (49,987)"](0001688757-25-000019|0) | (65.026) ["Loss from operations… (65,026)"](0001688757-25-000019|0) | improvement (computed) ["Loss from operations… (49,987)"](0001688757-25-000019|0) ["Loss from operations… (65,026)"](0001688757-25-000019|0) | | Net loss | (84.596) ["Net loss… (84,596)"](0001688757-25-000019|0) | (78.502) ["Net loss… (78,502)"](0001688757-25-000019|0) | worse (computed) ["Net loss… (84,596)"](0001688757-25-000019|0) ["Net loss… (78,502)"](0001688757-25-000019|0) | ### 3.2 Q3’25 acceleration (10‑Q) — evidence of U.S.-driven mix shift The Q3’25 10‑Q shows significant revenue growth and gross margin expansion YoY. **Quarterly results (Q3’25 vs Q3’24)** *(USD millions; “in thousands”)* | Metric | Q3’25 (ended Sep 30, 2025) | Q3’24 (ended Sep 30, 2024) | YoY | |---|---:|---:|---:| | Revenue | 53.782 ["Revenue… 53,782"](0001688757-25-000065|0) | 40.227 ["Revenue… 40,227"](0001688757-25-000065|0) | +33.8% (computed) ["Revenue… 53,782"](0001688757-25-000065|0) ["Revenue… 40,227"](0001688757-25-000065|0) | | Gross profit | 37.696 ["Gross profit… 37,696"](0001688757-25-000065|0) | 25.717 ["Gross profit… 25,717"](0001688757-25-000065|0) | +46.6% (computed) ["Gross profit… 37,696"](0001688757-25-000065|0) ["Gross profit… 25,717"](0001688757-25-000065|0) | | Gross margin | 70.1% ["Gross margin… 70.1"](0001688757-25-000065|0) | 63.9% ["Gross margin… 63.9"](0001688757-25-000065|0) | +620 bps (computed) ["Gross margin… 70.1"](0001688757-25-000065|0) ["Gross margin… 63.9"](0001688757-25-000065|0) | | Loss from operations | (4.025) ["Loss from operations… (4,025)"](0001688757-25-000065|0) | (13.139) ["Loss from operations… (13,139)"](0001688757-25-000065|0) | improvement (computed) ["Loss from operations… (4,025)"](0001688757-25-000065|0) ["Loss from operations… (13,139)"](0001688757-25-000065|0) | | Net loss | (11.146) ["Net loss… (11,146)"](0001688757-25-000065|0) | (16.682) ["Net loss… (16,682)"](0001688757-25-000065|0) | improvement (computed) ["Net loss… (11,146)"](0001688757-25-000065|0) ["Net loss… (16,682)"](0001688757-25-000065|0) | **Management’s stated “why” (Q3’25):** gross margin improved primarily due to **higher selling prices in the U.S.** ["Gross margin increased… attributable… sales within the United States… higher selling prices"](0001688757-25-000065|0) --- # 4) Balance sheet & capital structure — what you’re underwriting ## 4.1 FY2024 year-end balance sheet (10‑K) Key balance-sheet items (USD, in thousands): | Line item | Dec 31, 2024 | Dec 31, 2023 | |---|---:|---:| | Cash & cash equivalents | 90,347 ["Cash and cash equivalents… 90,347"](0001688757-25-000019|0) | 40,035 ["Cash and cash equivalents… 40,035"](0001688757-25-000019|0) | | Total assets | 346,831 ["Total assets… 346,831"](0001688757-25-000019|0) | 268,641 ["Total assets… 268,641"](0001688757-25-000019|0) | | Note payable (Oaktree), net | 219,577 ["Note payable, Oaktree… 219,577"](0001688757-25-000019|0) | 188,739 ["Note payable, Oaktree… 188,739"](0001688757-25-000019|0) | | Total liabilities | 293,736 ["Total liabilities… 293,736"](0001688757-25-000019|0) | 250,246 ["Total liabilities… 250,246"](0001688757-25-000019|0) | | Total shareholders’ equity | 53,095 ["Total shareholders’ equity… 53,095"](0001688757-25-000019|0) | 18,395 ["Total shareholders’ equity… 18,395"](0001688757-25-000019|0) | ## 4.2 Debt: term-loan structure & interest dynamics (10‑Q + 10‑K notes) As of **Sep 30, 2025**, the company discloses **$246.4 million outstanding under the Credit Agreement**, including capitalized accrued interest into principal. ["As of September 30, 2025… $246.4 million was outstanding"](0001688757-25-000065|0) At FY2024 year-end, the company discloses **$221.4 million outstanding** under the Credit Agreement. ["As of December 31, 2024, $221.4 million was outstanding"](0001688757-25-000019|0) **Why this matters:** the equity story is not just “revenue growth,” but also whether operating leverage can outpace interest expense (which is material in both FY and YTD disclosures). ["Interest expense… (20,829)"](0001688757-25-000019|0) ["Interest expense… (18,012)"](0001688757-25-000065|0) --- # 5) Cash flow & liquidity — how runway is managed ## 5.1 FY cash movement (10‑K) The FY2024 10‑K cash flow section shows year-end cash **$90.347 million**. ["Cash and cash equivalents at end of period… 90,347"](0001688757-25-000019|0) ## 5.2 9M’25 cash flow (10‑Q) For the **nine months ended Sep 30, 2025**, cash flow disclosure shows net cash used in operations and net decrease in cash. ["Operating activities… (50,728)"](0001688757-25-000065|0) ["Net increase/(decrease) in cash… (19,723)"](0001688757-25-000065|0) --- # 6) Near-term updates (2026 8‑Ks) — what changed *after* the last 10‑Q ## 6.1 Preliminary FY2025 results (Jan 12, 2026 press release furnished via 8‑K) The company disclosed **preliminary unaudited** ranges: - **Q4 2025 revenue:** $64.0–$65.0 million. ["Revenue… quarter ended December 31, 2025… between $64.0 million and $65.0 million"](0001688757-26-000004|1) - **FY2025 revenue:** $210.5–$211.5 million (≈27% growth vs 2024), including **U.S. Motiva sales $45.4–$45.9 million**. ["Revenue for fiscal year 2025… $210.5 million to $211.5 million"](0001688757-26-000004|1) ["including… $45.4 million and $45.9 million… United States"](0001688757-26-000004|1) - **Year-end 2025 cash:** ≈$75.5 million. ["year-end 2025 cash position… approximately $75.5 million"](0001688757-26-000004|1) ## 6.2 JPMorgan Healthcare Conference disclosure (Jan 14, 2026 8‑K) The company filed an 8‑K stating it **presented at the J.P. Morgan Healthcare Conference** and furnished materials as Exhibit 99.1. ["presented at the J.P. Morgan Healthcare Conference"](0001688757-26-000008|0) ["presentation materials… Exhibit 99.1"](0001688757-26-000008|0) --- # 7) Governance & incentives — what management is paid to do (Proxy: DEF 14A) ## 7.1 Board structure and declassification The 2025 proxy describes the board declassification process (phased in, concluding at the 2026 annual meeting). ["declassification… phased-in… concluding… 2026"](0001688757-25-000026|0) ## 7.2 Named executive officer (NEO) compensation (FY2024) — key table Below is the **Summary Compensation Table for FY2024** (USD): | Executive | Role | FY2024 Total comp | |---|---|---:| | Juan José Chacón Quirós | Former CEO | 2,601,271 ["Total… 2,601,271"](0001688757-25-000026|0) | | Filippo “Peter” Caldini | Interim CEO (joined Aug 2024) | 1,227,500 ["Total… 1,227,500"](0001688757-25-000026|0) | | Rajbir S. Denhoy | CFO | 1,120,391 ["Total… 1,120,391"](0001688757-25-000026|0) | | S. Ross Mansbach | General Counsel & CCO | 1,060,152 ["Total… 1,060,152"](0001688757-25-000026|0) | The same proxy breaks out **base salaries**, **target bonuses**, and **bonuses earned** for 2024. ["2024 Base Salary… 750,000"](0001688757-25-000026|0) ["2024 Target Bonus… 750,000"](0001688757-25-000026|0) ["2024 Bonus Earned… 487,500"](0001688757-25-000026|0) --- # 8) Risk map (from filings) — what can break the story ### 8.1 Regulatory & quality systems risk The company explicitly highlights reliance on maintaining (and obtaining) regulatory clearances/approvals and the potential for adverse impact if denied/delayed. ["Products… require clearance from the FDA… no assurance"](0001688757-25-000065|0) ### 8.2 Manufacturing concentration (Costa Rica) + capacity scaling Manufacturing is concentrated in Costa Rica and scaling requires time/certification; management notes the risk of being unable to fill orders if demand rises faster than capacity. ["manufactured… facilities in Costa Rica"](0001688757-25-000065|0) ["unable to fill all incoming orders"](0001688757-25-000019|0) ### 8.3 Supplier concentration The company describes reliance on a single-source supplier for medical-grade implantable silicone (Avantor). ["single-source… Avantor"](0001688757-25-000065|0) ### 8.4 Leverage + capital markets dependence Management states it may need to raise additional capital and warns about dilution / covenants, consistent with the debt burden disclosed. ["may seek to sell equity… or… debt financing"](0001688757-25-000065|0) ["$246.4 million was outstanding"](0001688757-25-000065|0) --- # 9) “Interactive” exploration paths (use this like a dashboard) Pick any path below as a lens; each is grounded in where the filings put the key facts. ### Path A — U.S. launch economics Focus on: U.S. sales growth, pricing/mix, gross margin expansion, and sales force productivity. ["Motiva… sales within the United States… higher selling prices"](0001688757-25-000065|0) ["generated $28.3 million… United States"](0001688757-25-000065|0) ### Path B — Operating leverage vs interest burden Focus on: SG&A trajectory vs gross profit growth, and interest expense / debt balance. ["SG&A… 121,041"](0001688757-25-000065|0) ["Interest expense… (18,012)"](0001688757-25-000065|0) ["$246.4 million… outstanding"](0001688757-25-000065|0) ### Path C — Geographic resilience Focus on: regional revenue shifts (EMEA/LatAm/APAC) and FX sensitivity. ["Revenue increased… Latin America… Asia-Pacific… EMEA"](0001688757-25-000065|0) ["fluctuations in currency exchange rates"](0001688757-25-000065|0) ### Path D — Governance & incentives Focus on: what the comp committee weights (revenue, opex, cash balance) and how equity awards vest. ["35%… revenue targets… 25%… OPEX… 25%… year-end cash balance"](0001688757-25-000026|0) ["vest over a four-year period"](0001688757-25-000026|0) --- If you want a “single-screen” underwriting view, the highest-signal filing anchors are: **FY2024 10‑K (filed Feb 28, 2025)**, **Q3’25 10‑Q (filed Nov 7, 2025)**, and the **Jan 2026 8‑Ks with preliminary FY2025 results**. ["filed… February 28, 2025"](0001688757-25-000065|0) ["filing_date… 20251107"](0001688757-25-000065|0) ["preliminary unaudited financial results… fiscal year ended December 31, 2025"](0001688757-26-000004|1)